Enoticumab
Enoticumab
Enoticumab (pronounced as /ɛnɒtɪkjuːmæb/) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Amgen, a multinational biopharmaceutical company.
Etymology
The term "Enoticumab" is derived from the International Nonproprietary Names (INN), where "mab" stands for monoclonal antibody, "ti" for targeting the immune system, "cu" for tumor, and "eno" is a unique stem.
Function
Enoticumab works by binding to the Notch 3 receptor, a protein that plays a crucial role in cell development and differentiation. By inhibiting this receptor, Enoticumab can potentially slow down or stop the growth of cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Notch 3: A human gene that encodes a member of the NOTCH family of proteins. Mutations in this gene have been associated with certain types of cancer.
- Amgen: A multinational biopharmaceutical company that develops and manufactures therapies for serious illnesses.
See Also
External links
- Medical encyclopedia article on Enoticumab
- Wikipedia's article - Enoticumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski